[1]徐生宇,李榕华,BROOKS Silas（法国）.CT灌注成像参数联合血清LOXL4、Caspase-4对原发性肝癌患者TACE术后复发的预测价值[J].陕西医学杂志,2026,(8):1052-1057.[doi:DOI:10.3969/j.issn.1000-7377.2026.08.006]
　XU Shengyu,LI Ronghua,BROOKS Silas.Predictive value of CT perfusion parameters combined with serum LOXL4 and Caspase-4 for recurrence after TACE in patients with primary liver cancer[J].,2026,(8):1052-1057.[doi:DOI:10.3969/j.issn.1000-7377.2026.08.006]
点击复制

CT灌注成像参数联合血清LOXL4、Caspase-4对原发性肝癌患者TACE术后复发的预测价值

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年8期
页码:
1052-1057
栏目:
临床研究
出版日期:
2026-08-05

文章信息/Info

Title:
Predictive value of CT perfusion parameters combined with serum LOXL4 and Caspase-4 for recurrence after TACE in patients with primary liver cancer
作者:
徐生宇1; 2; 李榕华1; 2; BROOKS Silas1（法国）
（1.南通大学，江苏 南通 226019；2.海安市人民医院介入与血管外科，江苏 海安 226600）
Author(s):
XU Shengyu1; 2; LI Ronghua1; 2; BROOKS Silas1
（1.Nantong University,Nantong 226019,China;2.Department of Interventional and Vascular Surgery,Hai’an People’s Hospital,Hai’an 226600,China)
关键词:
原发性肝癌; 经导管肝动脉化疗栓塞术; CT灌注成像; 赖氨酰氧化酶样蛋白4; 半胱氨酸天冬氨酸蛋白酶-4; 复发
Keywords:
Primary liver cancer; Transarterial chemoembolization; CT perfusion; Lysyl oxidase-like 4; Caspase-4; Recurrence
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7377.2026.08.006
文献标志码:
A
摘要:
目的：探讨CT灌注成像（CTP）参数联合血清赖氨酰氧化酶样蛋白4（LOXL4）、半胱氨酸天冬氨酸蛋白酶-4（Caspase-4）对原发性肝癌（PLC）患者经导管肝动脉化疗栓塞术（TACE）治疗后复发的预测价值。方法：选取接受TACE治疗的PLC患者119例。所有患者于TACE术后1个月行CTP检查，记录血流量（BF）、血容量（BV）、肝动脉灌注指数（HAI）及门静脉灌注量（PVP）等指标；同期采用ELISA法测定血清LOXL4和Caspase-4浓度。术后随访12个月，根据有无复发划分组别。采用多因素Logistic回归分析PLC患者TACE术后复发的影响因素，并建立联合预测模型。通过受试者工作特征（ROC）曲线评估CTP参数、血清LOXL4和Caspase-4各指标及联合模型对患者术后复发的预测效能。结果：随访期间复发41例，其余78例未复发。TACE术后1个月，复发组BF、BV、HAI值及血清LOXL4、Caspase-4水平高于未复发组，PVP值低于未复发组（均P<0.05）。BF、HAI、血清LOXL4及Caspase-4为PLC患者TACE术后复发的独立影响因素（均P<0.05），并以这四项指标构建联合预测模型。联合模型预测患者术后复发的曲线下面积（AUC）高于BF、HAI、血清LOXL4及Caspase-4单独预测的AUC（均P<0.05）。结论：CTP参数BF、HAI及血清LOXL4、Caspase-4是PLC患者TACE术后复发的影响因素，且四项指标联合构建的模型对患者TACE术后复发的预测效能较高。
Abstract:
Objective:To investigate the predictive value of CT perfusion (CTP) parameters combined with serum lysyl oxidase-like 4 (LOXL4) and Caspase-4 for recurrence after transarterial chemoembolization (TACE) in patients with primary liver cancer (PLC).Methods:A total of 119 PLC patients who received TACE treatment were selected.All patients underwent CTP examination at 1 month after TACE,and indicators including blood flow (BF),blood volume (BV),Hepatic Arterial Perfusion Index (HAI) and portal venous perfusion (PVP) were recorded;serum concentrations of LOXL4 and Caspase-4 were measured by ELISA at the same period.Postoperative follow-up was conducted for 12 months,and patients were grouped according to the presence or absence of recurrence.Multivariate Logistic regression was used to analyze the influencing factors of recurrence after TACE in PLC patients,and a combined prediction model was established.ROC curve was used to evaluate the predictive efficacy of CTP parameters,serum LOXL4,Caspase-4 and the combined model for postoperative recurrence.Results:During the follow-up period,41 cases developed recurrence,and the remaining 78 cases had no recurrence.At 1 month after TACE,the levels of BF,BV,HAI and serum LOXL4,Caspase-4 in the recurrence group were higher than those in the non-recurrence group,while the PVP was lower than that in the non-recurrence group (all P<0.05).BF,HAI,serum LOXL4 and Caspase-4 were independent influencing factors for recurrence after TACE in PLC patients (all P<0.05),and the combined prediction model was constructed with these four indicators.The AUC of the combined model for predicting postoperative recurrence was higher than the AUC of BF,HAI,serum LOXL4 and Caspase-4 alone (all P<0.05).Conclusion:CTP parameters BF and HAI,as well as serum LOXL4 and Caspase-4 are influencing factors for recurrence after TACE in PLC patients,and the model jointly constructed by the four indicators has favorable predictive efficacy for recurrence after TACE.

参考文献/References:

[1]TAN H,XU Y,ZHANG C,et al.Development and validation of a nomogram for predicting early recurrence in patients undergoing different courses of postoperative adjuvant transarterial chemoembolisation[J].BMC Gastroenterol,2025,25(1):422.
[2]张鹏,李晓利,马光辉.TACE联合索拉非尼治疗肝细胞癌根治术后微血管侵犯的临床效果[J].肝胆胰外科杂志,2025,37(12):802-808,813.
[3]俞斌,印于,杨俊,等.TACE联合CBCT引导下MWA同步治疗小肝癌的临床疗效与安全性分析[J].介入放射学杂志,2025,34(12):1321-1327.
[4]张海峰,黄舒心,杨苗.CT灌注成像评估经导管动脉化疗栓塞联合阿帕替尼治疗中晚期肝细胞癌的价值[J].河南医学研究,2023,32(22):4079-4082.
[5]葛敬军,张嘉进,柯炜炜,等.肝脏CT灌注成像参数分析原发性肝癌TACE术后残余病灶的价值[J].肝脏,2025,30(9):1230-1233.
[6]高越,万里新,曾庆,等.原发性肝癌患者介入治疗后血清LOXL4水平与复发的相关性分析[J].中西医结合肝病杂志,2023,33(8):698-701.
[7]王楚涵.基于一站式肝脾CTP与门静脉CTV的三维血流动力学模型对肝硬化TIPS患者肝脾血流灌注和门静脉压力的评估价值研究[D].苏州:苏州大学,2023.
[8]高芳,常虹,穆华,等.血清分泌型Dickkopf相关蛋白1及赖氨酰氧化酶样蛋白4与肝癌术后早期进展的关系及其预测价值[J].中国临床医生杂志,2025,53(8):974-978.
[9]ZHAO L,PEI R,DING Y,et al.LOXL4 shuttled by tumor cells-derived extracellular vesicles promotes immune escape in hepatocellular carcinoma by activating the STAT1/PD-L1 axis[J].J Immunother,2024,47(2):64-76.
[10]杨瑜婧,刘立业,杨慧芳,等.ALBI、Caspase-4联合肿瘤ADC值对原发性肝癌患者TACE术后复发的预测价值[J].肝脏,2025,30(12):1637-1641.
[11]陈海琳,杨涛,周云.原发性肝癌患者双源CT全肝灌注成像特点及对TACE术后残余病灶的评估价值[J].实用肝脏病杂志,2024,27(5):769-772.
[12]李建林,李娅,郑秋然,等.125I放射性粒子植入联合TACE治疗原发性肝癌患者疗效研究[J].实用肝脏病杂志,2025,28(6):894-897.
[13]王建国,刘伟,陈志强,等.CTPI灌注参数联合增强CT在原发性肝癌患者TACE术后评估中的应用[J].中国医学工程,2022,30(1):112-116.
[14]高延忠,王明利.CT联合MRI评估肝细胞癌病理分级可行性研究[J].陕西医学杂志,2022,51(3):375-377,381.
[15]覃小宾,李祖隆,曾胜澜,等.赖氨酰氧化酶家族在肝细胞癌发生发展中的作用[J].临床肝胆病杂志,2022,38(3):682-687.
[16]TIAN M,LIU W,JIN L,et al.LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis[J].Int J Clin Exp Pathol,2015,8(4):3892-3900.
[17]马丽,陈文,赵斌,等.赖氨酰氧化酶样蛋白4在肝细胞癌中的表达及其预后相关性分析[J].井冈山大学学报（自然科学版）,2024,45(5):46-57.
[18]TAO S,YANG Y.Pyroptosis drives tumor progression and immune evasion in hepatocellular carcinoma:A single-cell and spatial transcriptomic study[J].Discov Oncol,2025,16(1):834-834.
[19]WANG J,HUANG Z,LU H,et al.A pyroptosis-related gene signature to predict patients’ prognosis and immune landscape in liver hepatocellular carcinoma[J].Comput Math Methods Med,2022,2022:1258480.
[20]杨兰,许诗杰,包华鑫.肝细胞癌患者TACE术后血清FGFR1、VEGFA和IRX5水平变化及其与疗效的关系研究[J].实用肝脏病杂志,2025,28(6):890-893.
[21]GUO X,SONG J,ZHU L,et al.Multiparametric MRI-based radiomics and clinical nomogram predicts the recurrence of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization[J].BMC Cancer,2025,25(1):683.
[22]ZHAO J,MENG Y,JIANG Z,et al.Construction and validation of a predictive model for post-TACE recurrence risk in hepatocellular carcinoma:A retrospective cohort study[J].J Hepatocell Carcinoma,2026,13:584698.
[23]ZHOU L,ZHENG L,ZHANG K,et al.Radiomic biomarkers for the recurrence prediction of hepatocellular carcinoma treated with postoperative TACE:A multicenter retrospective study[J].Eur J Radiol,2025,193:112442.
[24]WANG H,LI J,OUYANG Y,et al.Multiparametric MRI based deep learning model for prediction of early recurrence of hepatocellular carcinoma after SR following TACE[J].J Cancer Res Clin Oncol,2024,150(10):448.
[25]都鹏宇,赵霞,曾锦,等.CT增强纹理分析原发性肝癌介入治疗后短期复发及转移的预测价值[J].影像研究与医学应用,2025,9(12):40-43.
[26]ZHANG S,WANG W,ZHANG X,et al.The nVR model:Prediction of LI-RADS treatment response nonviable recurrence of hepatocellular carcinoma after primary transarterial chemoembolization[J].Abdom Radiol (NY),2025,50(11):5197-5210.
[27]LIU J,DING X,ZHANG Y,et al.A clinical-imaging nomogram for predicting early recurrence in patients with solitary hepatocellular carcinoma after postoperative adjuvant TACE[J].J Hepatocell Carcinoma,2025,12:1835-1847.
[28]金巧薇,卜顺林,吴建伟.MRI多参数成像及动态增强检查对肝细胞肝癌特征性影像表现及鉴别诊断分析[J].中国临床研究,2025,38(2):271-274.
[29]GUO Z Y,TU M Y,YANG Y S,et al.Nomogram for predicting post-transarterial chemoembolization survival in recurrent patients with hepatitis B virus-associated hepatocellular carcinoma[J].Sci Rep,2025,15(1):42367.
[30]ZHANG R,LI T,FAN F,et al.Identification and validation of an explainable machine learning model for vascular depression diagnosis in the older adults:a multicenter cohort study[J].BMC Med,2025,23(1):448.
[31]李鹏政,程保国,刘金展,等.CT灌注成像参数及血清癌胚抗原和甲胎蛋白在监测原发性肝癌TACE术后复发中的应用[J].实用医学杂志,2026,42(2):176-184.

相似文献/References:

[1]郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析*[J].陕西医学杂志,2019,(7):850.
[2]李 珣,张祥林.肝动脉化疗栓塞联合恩替卡韦对原发性肝癌治疗效果及对患者血清中恶性肿瘤特异性生长因子的影响[J].陕西医学杂志,2019,(7):873.
　LI Xun,ZHANG Xianglin..Efficacy observation and TSGF change in primary hepatocellular carcinoma by TACE and entecavir[J].,2019,(8):873.
[3]陶 琳.原发性肝癌患者化疗后抗菌药物的应用及继发感染的危险因素分析[J].陕西医学杂志,2023,52(1):89.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
　TAO Lin.Application of antibiotics and risk factors of secondary infection in patients with primary liver cancer after chemotherapy[J].,2023,52(8):89.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
[4]刘立友,吴东洋,蔡青山,等.原发性肝癌组织中层粘连蛋白3、黏着斑激酶蛋白表达及其与患者临床病理特征和预后关系研究[J].陕西医学杂志,2023,52(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
　LIU Liyou,WU Dongyang,CAI Qingshan,et al.Expression of LAMA3 and FAK proteins in primary liver cancer and their relationship with clinicopathological features and prognosis of patients[J].,2023,52(8):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
[5]刘贤国,徐红玉,朱 江.原发性肝癌伴门静脉癌栓产生机制及经导管肝动脉化疗栓塞术联合其他介入方案治疗研究进展[J].陕西医学杂志,2023,52(10):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
　LIU Xianguo,XU Hongyu,ZHU Jiang.Research progress on mechanism of thrombus formation of primary liver cancer with portal vein cancer and application progress of TACE combined with other interventional protocols[J].,2023,52(8):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
[6]李晓勤,王 群,何晓兰,等.多模式镇痛对原发性肝癌患者休斯顿疼痛情况调查表评分及血清结合珠蛋白水平的影响[J].陕西医学杂志,2024,(4):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
　LI Xiaoqin,WANG Qun,HE Xiaolan,et al.InfLuences of multimodal analgesia on HPOI score and serum haptoglobin level in patients with hepatocellular carcinoma[J].,2024,(8):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
[7]孟凡岗,刘文宇,甄立军,等.原发性肝癌组织长链非编码RNA JPX、微小RNA-371a-5p表达水平及其与患者术后5年预后关系研究[J].陕西医学杂志,2024,(8):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]
　MENG Fangang,LIU Wenyu,ZHEN Lijun,et al.Expression levels of long non-coding RNA JPX and microRNA-371a-5p in primary liver cancer tissues and their relationship with 5-year prognosis of patients after surgery[J].,2024,(8):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]
[8]万仁均,罗文强,刘鑫.血清HSP90α、GPC3、AFP-L3水平对早期原发性肝细胞癌的诊断价值[J].陕西医学杂志,2025,54(9):1248.[doi:DOI:10.3969/j.issn.1000-7377.2025.09.017]
　WAN Renjun,LUO Wenqiang,LIU Xin.Diagnostic value of serum HSP90α,GPC3,and AFP-L3 levels in early primary hepatocellular carcinoma[J].,2025,54(8):1248.[doi:DOI:10.3969/j.issn.1000-7377.2025.09.017]
[9]罗华权,古代娇,李森林,等.CLEC1B、CCR7、GPSM2在原发性肝癌组织中的表达及临床意义[J].陕西医学杂志,2025,54(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2025.09.019]
　LUO Huaquan,GU Daijiao,LI Senlin,et al.Expression and clinical significance of CLEC1B,CCR7 and GPSM2 in primary liver cancer[J].,2025,54(8):1259.[doi:DOI:10.3969/j.issn.1000-7377.2025.09.019]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82070624）；江苏省医学会医学科研项目[SYH-3202735-0168（2025045）]
更新日期/Last Update: 2026-08-13